I work with leaders in complex biomedical environments where innovation stalls not because discovery has failed, but because decisions do not become binding.

​

This work sits at the point where evidence, incentives, and accountability begin to diverge - and where experienced judgement is required to determine whether a system is structurally sound before irreversible commitments are made.

​

My focus is not optimisation or execution, but decision integrity: helping leadership teams understand what is actually being decided, where risk moves once action is taken, and whether coherence will hold under regulatory, commercial, and reputational pressure.

 

Where decisions typically break down

 

In regulated biomedicine, failure rarely comes from a lack of science.
It arises when evidence is interpreted differently across functions, accountability remains diffuse, and decisions harden without being consciously designed.

​

I work with leaders at these fracture points to clarify:

• how evidence is being translated into value judgements

• where access and adoption assumptions diverge from reality

• whether economic logic remains coherent once decisions are taken

• how governance and risk are embedded — or deferred

 

The objective is not certainty, but coherence: ensuring that when a decision is made, its consequences are understood, owned, and defensible.

​

​​​​​​​​​​​​​​​​​​​​Credibility

​

This perspective has been shaped through senior regulatory, medical, and commercial leadership roles across global biomedical organisations, spanning infectious diseases, immunology, aesthetics, and orphan and rare disease contexts.

​

It includes deep experience in antimicrobial resistance, where the failure of evidence to translate into durable, decision-binding outcomes is particularly visible.

​

The work reflects lived exposure to regulatory scrutiny, commercial consequence, and the downstream accountability that follows once decisions become irreversible.

​

Call to action 

 

If you’re navigating scientific complexity, regulatory scrutiny, or market misalignment — and need experienced judgement rather than generic playbooks — I’m open to a conversation.

Contact me using harpal.dhillon@protonmail.com or Explore and Connect on LinkedIn